Veritas Pharma to Attend the European Respiratory Society International Congress and the Lift's Canadian Cannabis Business Conference & Cannabis Expo Next Month

Aug 18, 2016, 09:00 ET from Veritas Pharma Inc.

VANCOUVER, British Columbia, August 18, 2016 /PRNewswire/ --

Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), ("Veritas" or the "Company"), is pleased to announce that it will be attending three important events next month -the European Respiratory Society International Congress in London, UK as well as the Lift's Canadian Cannabis Business conference and Cannabis Expo in Vancouver, Canada.  These meetings will inform the Company about the current state of cannabis research from different parts of the world, along with further insight about the legalization and public health & safety concerns of medicinal cannabis from a Canadian perspective.

From September 3-7, the European Respiratory Society will have posters and related discussions about the health outcomes, socioeconomic impact, and the respiratory effects of cannabis use.  More information can be found at http://erscongress.org

From September 12-16, The Canadian Cannabis Business Conference will examine the different aspects of the emerging medical and recreational cannabis industry in Canada.  The range of topics include: law and regulations, public health and safety, finance and banking, public and government relations, as well as marketing and advertising. (Lift is a Canadian online information portal and meeting organizer that aims to 'facilitate conversations and spread credible information in an era of rapid legitimization and growth of the new cannabis economy').  More information about this event can be found at https://events.lift.co/event/ccbcvancouver2016

From September 17-18, the Lift Cannabis Expo will have over 100 businesses from around the world showcasing their best cannabis products and services for consumers.  More information about this event can be found at https://events.lift.co/expo/vancouver2016

As well, Cannevert Therapeutics Ltd, which is Veritas' exclusive partner and high-level R&D arm, is currently preparing its next quarterly research report.  The Company expects to receive it toward the end of Q3 or early Q4 this year.

About Veritas Pharma Inc. 

Veritas Pharma Inc. is an emerging discovery and IP development company, advancing the science behind medical cannabis. The company's current R&D efforts are to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for real science to support medical marijuana claims.

Our unique value proposition employs a whole plant methodology, using a low cost research and development model to help drive shareholder value and speed-to-market. Veritas is led by strong management, bringing together veteran academic pharmacologists, anesthetists & chemists. The company's commercial mission is to patent protect its IP (cultivars/ strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: veritaspharmainc.com

On behalf of the Board of Directors; Veritas Pharma Inc.

"Dr. Lui Franciosi"

Dr. Lui Franciosi

Chief Executive Officer

 

Further information about the Company is available on our website at http://www.veritaspharmainc.com or under our profile on SEDAR at http://www.sedar.com and on the CSE website at http://www.thecse.com 

The CSE has not reviewed, nor approved or disapproved the content of this press release. 

DISCLAIMER: Forward-Looking Information: This news release contains certain forward-looking information. All information, other than information regarding historic fact that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future is forward-looking information. The forward-looking information contained in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. With respect to the forward-looking information contained in this news release, the Company has made assumptions regarding, among other things, the results of the research and development activities, and the continued ability of the Company to raise additional financing. The forward-looking information contained in this news release is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from current expectations, including the any future changes to laws pertaining to the use of cannabis derived pharmaceuticals, prices and demand for cannabis derived pharmaceuticals, future currency and interest rates. Additionally, if the Company is unable to obtain additional financing, the Company may be required to curtail activities and/or liquidate its assets or the Company's creditors may seek to seize its assets. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable law, the Company disclaims any obligation to update or modify such forward-looking information, either because of new information, future events or for any other reason. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. The CSE has not reviewed, nor approved or disapproved the contents of this press release.


Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1-416-918-6785
Email: ir@veritaspharmainc.com
Website: http://www.veritaspharmainc.com

SOURCE Veritas Pharma Inc.